RASA1 functions in EPHB4 signaling pathway to suppress endothelial mTORC1 activity

Journal of Clinical Investigation

Volumn 124, Issue 6, 2014, Pages 2774-2784

  Kawasaki, Jun ^a   Aegerter, Sandrine ^a   Fevurly, R Dawn ^a   Mammoto, Akiko ^a   Mammoto, Tadanori ^a   Sahin, Mustafa ^a   Mably, John D ^b,c   Fishman, Steven J ^a   Chan, Joanne ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HAMPTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; EPHRIN B2; EPHRIN RECEPTOR B4; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RAS P21 PROTEIN ACTIVATOR 1; RAS PROTEIN; UNCLASSIFIED DRUG;

ALLELE; ANGIOGENESIS; ANIMAL EXPERIMENT; ARTERIOVENOUS MALFORMATION; ARTERY BLOOD FLOW; ARTICLE; BLOOD VESSEL FUNCTION; CONTROLLED STUDY; EMBRYO; ENDOTHELIUM CELL; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ZEBRA FISH;

ANIMALS; BLOOD VESSELS; ENDOTHELIAL CELLS; HUMANS; MULTIPROTEIN COMPLEXES; MUSCULAR DYSTROPHY, ANIMAL; P120 GTPASE ACTIVATING PROTEIN; RECEPTOR, EPHB4; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; ZEBRAFISH; ZEBRAFISH PROTEINS;

EID: 84902180002     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI67084     Document Type: Article

References (69)

1. Marler JJ, et al. Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: report of 2 cases. Pediatrics. 2002;109(2):E37.
2. Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg. 1982;69(3):412-422.
3. Boon LM, Ballieux F, Vikkula M. Pathogenesis of vascular anomalies. Clin Plast Surg. 2011;38(1):7-19.
4. Greene AK. Vascular anomalies: current overview of the field. Clin Plast Surg. 2011;38(1):1-5.
5. Eerola I, et al. Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am J Hum Genet. 2003;73(6):1240-1249.
6. Boon LM, Mulliken JB, Vikkula M. RASA1: variable phenotype with capillary and arteriovenous malformations. Curr Opin Genet Dev. 2005;15(3):265-269.
7. Revencu N, et al. Parkes Weber syndrome, vein of Galen aneurysmal malformation, and other fastflow vascular anomalies are caused by RASA1 mutations. Hum Mutat. 2008;29(7):959-965.
8. de Wijn RS, Oduber CE, Breugem CC, Alders M, Hennekam RC, van der Horst CM. Phenotypic variability in a family with capillary malformations caused by a mutation in the RASA1 gene. Eur J Med Genet. 2012;55(3):191-195.
9. Revencu N, et al. RASA1 Mutations and Associated Phenotypes in 68 Families with Capillary Malformation-Arteriovenous Malformation. Hum Mutat. 2013;34(12):1632-1641.
10. Liu AS, Mulliken JB, Zurakowski D, Fishman SJ, Greene AK. Extracranial arteriovenous malformations: natural progression and recurrence after treatment. Plast Reconstr Surg. 2010;125(4):1185-1194.
11. Henkemeyer M, et al. Vascular system defects and neuronal apoptosis in mice lacking ras GTPase-activating protein. Nature. 1995;377(6551):695-701.
12. Brouillard P, Vikkula M. Genetic causes of vascular malformations. Hum Mol Genet. 2007;16(spec no. 2):R140-R149.
13. Bernards A. GAPs galore! A survey of putative Ras superfamily GTPase activating proteins in man and Drosophila. Biochim Biophys Acta. 2003;1603(2):47-82.
14. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3(1):11-22.
15. Friedman E, Gejman PV, Martin GA, McCormick F. Nonsense mutations in the C-terminal SH2 region of the GTPase activating protein (GAP) gene in human tumours. Nat Genet. 1993;5(3):242-247.
16. Mitsudomi T, Friedman E, Gejman PV, McCormick F, Gazdar AF. Genetic analysis of the catalytic domain of the GAP gene in human lung cancer cell lines. Hum Genet. 1994;93(1):27-31.
17. Lapinski PE, et al. RASA1 maintains the lymphatic vasculature in a quiescent functional state in mice. J Clin Invest. 2012;122(2):733-747.
18. Margolis B, et al. The tyrosine phosphorylated carboxyterminus of the EGF receptor is a binding site for GAP and PLC-γ. EMBO J. 1990;9(13):4375-4380.
19. Kaplan DR, Morrison DK, Wong G, McCormick F, Williams LT. PDGF β-receptor stimulates tyrosine phosphorylation of GAP and association of GAP with a signaling complex. Cell. 1990;61(1):125-133.
20. Holland SJ, et al. Juxtamembrane tyrosine residues couple the Eph family receptor EphB2/Nuk to specific SH2 domain proteins in neuronal cells. EMBO J. 1997;16(13):3877-3888.
21. Adams RH, et al. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev. 1999;13(3):295-306.
22. Gerety SS, Wang HU, Chen ZF, Anderson DJ. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell. 1999;4(3):403-414.
23. Wang HU, Chen ZF, Anderson DJ. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell. 1998;93(5):741-753.
24. Swift MR, Weinstein BM. Arterial-venous specification during development. Circ Res. 2009;104(5):576-588.
25. Cowan CA, et al. Ephrin-B2 reverse signaling is required for axon pathfinding and cardiac valve formation but not early vascular development. Dev Biol. 2004;271(2):263-271.
26. Makinen T, et al. PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature. Genes Dev. 2005;19(3):397-410.
27. Foo SS, et al. Ephrin-B2 controls cell motility and adhesion during blood-vessel-wall assembly. Cell. 2006;124(1):161-173.
28. Anand S, et al. MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med. 2010;16(8):909-914.
29. Pelster B, Burggren WW. Disruption of hemoglobin oxygen transport does not impact oxygendependent physiological processes in developing embryos of zebra fish (Danio rerio). Circ Res. 1996;79(2):358-362.
30. Barrionuevo WR, Burggren WW. O2 consumption and heart rate in developing zebrafish (Danio rerio): influence of temperature and ambient O2. Am J Physiol. 1999;276(2 pt 2):R505-R513.
31. Ekker SC. Morphants: a new systematic vertebrate functional genomics approach. Yeast. 2000;17(4):302-306.
32. Lawson ND, Weinstein BM. In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev Biol. 2002;248(2):307-318.
33. Traver D, Paw BH, Poss KD, Penberthy WT, Lin S, Zon LI. Transplantation and in vivo imaging of multilineage engraftment in zebrafish bloodless mutants. Nat Immunol. 2003;4(12):1238-1246.
34. Isogai S, Horiguchi M, Weinstein BM. The vascular anatomy of the developing zebrafish: an atlas of embryonic and early larval development. Dev Biol. 2001;230(2):278-301.
35. Choi J, et al. Aplexone targets the HMG-CoA reductase pathway and differentially regulates arteriovenous angiogenesis. Development. 2011;138(6):1173-1181.
36. Tong J, Elowe S, Nash P, Pawson T. Manipulation of EphB2 regulatory motifs and SH2 binding sites switches MAPK signaling and biological activity. J Biol Chem. 2003;278(8):6111-6119.
37. Isogai S, Lawson ND, Torrealday S, Horiguchi M, Weinstein BM. Angiogenic network formation in the developing vertebrate trunk. Development. 2003;130(21):5281-5290.
38. Roman BL, et al. Disruption of acvrl1 increases endothelial cell number in zebrafish cranial vessels. Development. 2002;129(12):3009-3019.
39. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12(1):9-22.
40. Zygmunt T, et al. In parallel interconnectivity of the dorsal longitudinal anastomotic vessels requires both VEGF signaling and circulatory flow. J Cell Sci. 2012;125(pt 21):5159-5167.
41. Junttila TT, et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell. 2009;15(5):429-440.
42. Serra V, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008;68(19):8022-8030.
43. Verheijen JC, Zask A. Phosphatidylinositol 3-kinase (PI3K) inhibitors as anticancer drugs. Drugs Fut. 2007;32(6):537-547.
44. Yan L, Findlay GM, Jones R, Procter J, Cao Y, Lamb RF. Hyperactivation of mammalian target of rapamycin (mTOR) signaling by a gain-offunction mutant of the Rheb GTPase. J Biol Chem. 2006;281(29):19793-19797.
45. Li Y, Corradetti MN, Inoki K, Guan KL. TSC2: filling the GAP in the mTOR signaling pathway. Trends Biochem Sci. 2004;29(1):32-38.
46. Kawakami K. Transgenesis and gene trap methods in zebrafish by using the Tol2 transposable element. Methods Cell Biol. 2004;77:201-222.
47. Kawakami K. Transposon tools and methods in zebrafish. Dev Dyn. 2005;234(2):244-254.
48. Kawakami K. Tol2: a versatile gene transfer vector in vertebrates. Genome Biol. 2007;8(Suppl 1):S7.
49. Kwan KM, et al. The Tol2kit: a multisite gateway-based construction kit for Tol2 transposon transgenesis constructs. Dev Dyn. 2007;236(11):3088-3099.
50. Pamonsinlapatham P, et al. P120-Ras GTPase activating protein (RasGAP): a multi-interacting protein in downstream signaling. Biochimie. 2009;91(RasGAP):320-328.
51. Scheffzek K, et al. The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science. 1997;277(5324):333- 338.
52. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nature reviews Cancer. 2011;11(11):761-774.
53. Johnson GL, Vaillancourt RR. Sequential protein kinase reactions controlling cell growth and differentiation. Curr Opin Cell Biol. 1994;6(2):230-238.
54. Rodriguez-Viciana P, et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature. 1994;370(6490):527-532.
55. Rodriguez-Viciana P, Marte BM, Warne PH, Downward J. Phosphatidylinositol 3' kinase: one of the effectors of Ras. Philos Trans R Soc Lond B Biol Sci. 1996;351(1336):225-231.
56. Rodriguez-Viciana P, Warne PH, Vanhaesebroeck B, Waterfield MD, Downward J. Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. EMBO J. 1996;15(10):2442-2451.
57. Castellano E, Downward J. RAS interaction with PI3K: more than just another effector pathway. Genes Cancer. 2011;2(3):261-274.
58. Kim YH, Hu H, Guevara-Gallardo S, Lam MT, Fong SY, Wang RA. Artery and vein size is balanced by Notch and ephrin B2/EphB4 during angiogenesis. Development. 2008;135(22):3755-3764.
59. Herbert SP, et al. Arterial-venous segregation by selective cell sprouting: an alternative mode of blood vessel formation. Science. 2009;326(5950):294-298.
60. Davis S, et al. Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity. Science. 1994;266(5186):816-819.
61. Lam C, Bouffet E, Tabori U, Mabbott D, Taylor M, Bartels U. Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors. Pediatr Blood Cancer. 2010;54(3):476-479.
62. Hammill AM, et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer. 2011;57(6):1018-1024.
63. Mammoto A, et al. A mechanosensitive transcriptional mechanism that controls angiogenesis. Nature. 2009;457(7233):1103-1108.
64. Connor KM, et al. Quantification of oxygeninduced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat Protoc. 2009;4(11):1565-1573.
65. Minami M, Koyama T, Wakayama Y, Fukuhara S, Mochizuki N. EphrinA/EphA signal facilitates insulin-like growth factor-I-induced myogenic differentiation through suppression of the Ras/extracellular signal-regulated kinase 1/2 cascade in myoblast cell lines. Mol Biol Cell. 2011;22(18):3508-3519.
66. Lin KT, Sloniowski S, Ethell DW, Ethell IM. Ephrin-B2-induced cleavage of EphB2 receptor is mediated by matrix metalloproteinases to trigger cell repulsion. J Biol Chem. 2008;283(43):28969-28979.
67. Ma L, et al. Identification of S664 TSC2 phosphorylation as a marker for extracellular signalregulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Cancer Res. 2007;67(15):7106-7112.
68. Chan J, et al. Morphogenesis of prechordal plate and notochord requires intact Eph/ephrin B signaling. Dev Biol. 2001;234(2):470-482.
69. Chan J, Bayliss PE, Wood JM, Roberts TM. Dissection of angiogenic signaling in zebrafish using a chemical genetic approach. Cancer Cell. 2002;1(3):257-267.